Assessment of the Long-Term Safety and Efficacy of Bempedoic Acid (CLEAR Harmony OLE)

Esperion Therapeutics logo

Esperion Therapeutics

Status and phase

Completed
Phase 3

Conditions

Atherosclerotic Cardiovascular Disease
Hypercholesterolemia

Treatments

Drug: bempedoic acid

Study type

Interventional

Funder types

Industry

Identifiers

NCT03067441
2016-004115-12 (EudraCT Number)
1002-050

Details and patient eligibility

About

The purpose of this study is to see if bempedoic acid (ETC-1002) is safe and well-tolerated in patients with high cardiovascular risk and elevated LDL cholesterol that is not adequately controlled by their current therapy.

Enrollment

1,462 patients

Sex

All

Ages

18+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

Successfully completed CLEAR Harmony (1002-040) parent study

Exclusion criteria

  • Experienced a treatment-related SAE that led to study drug discontinuation in the CLEAR Harmony (1002-040) parent study.
  • Medical condition requires lipid measurement and/or adjustment of background lipid-regulating therapy.

Trial design

1,462 participants in 1 patient group

Open-Label bempedoic acid
Experimental group
Description:
bempedoic acid 180 mg tablet
Treatment:
Drug: bempedoic acid

Trial documents
2

Trial contacts and locations

0

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location

Resources

© Copyright 2024 Veeva Systems